Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells

被引:62
作者
Guo, J
Zhang, MG
Wang, BC
Yuan, ZL
Guo, ZH
Chen, TY
Yu, YZ
Qin, ZH
Cao, XT
机构
[1] Mil Med Univ 2, Inst Immunol, Shanghai 200433, Peoples R China
[2] PLA, Jinan Gen Hosp, Jinan, Peoples R China
关键词
fractalkine; antitumor immunity; dendritic cells; T cells; lung carcinoma;
D O I
10.1002/ijc.10816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fractalkine (FK, also called neurotactin or CX3CLI) is a CX3C chemokine that can chemoattract T lymphocytes, monocytes and NK cells. In our study, we investigated the induction of antitumor response by FK gene transfer. FK gene-modified 3LL lung carcinoma cells (3LL-FK) could both secrete soluble form and express membrane-bound form of FK. The tumor growth of 3LL-FK was decreased. Vaccination with 3LL-FK was effective in the induction of protective immunity and CTL. In vivo depletion analysis demonstrated that CD8(+) T cells are the main participating cells of the antitumor response. Obvious infiltrations of CD8(+) T cells, CD4(+) T cells and dendritic cells (DC) were observed in the tumor sites, suggesting that 3LL-FK might induce antitumor immunity through chemoattraction and activation of T cells and DC. Then we investigated the chemoattraction and activation of DC by 3LL-FK. Chemotaxis assay showed that the supernatants of 3LL-FK could chemoattract immature DC, which were found to express FK receptor CX3CRI, and the immature DC could obviously adhere to 3LL-FK. Adherence of DC to 3LL-FK resulted in phenotypic maturation and upregulated IL-12 secretion of DC, and more strong stimulation of allogeneic T-cell proliferation by DC. The increased production of IL-2 and IFNgamma in 3LL-FK tumor tissue was also observed. Our data suggested that FK gene transfer to tumor cells could induce T-cell-dependent antitumor immunity through chemoattraction and activation of DC. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:212 / 220
页数:9
相关论文
共 46 条
  • [31] RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: Role of immune cell subpopulations
    Mule, JJ
    Custer, M
    Averbook, B
    Yang, JC
    Weber, JS
    Goeddel, DV
    Rosenberg, SA
    Schall, TJ
    [J]. HUMAN GENE THERAPY, 1996, 7 (13) : 1545 - 1553
  • [32] Involvement of chemokine receptors in breast cancer metastasis
    Müller, A
    Homey, B
    Soto, H
    Ge, NF
    Catron, D
    Buchanan, ME
    McClanahan, T
    Murphy, E
    Yuan, W
    Wagner, SN
    Barrera, JL
    Mohar, A
    Verástegui, E
    Zlotnik, A
    [J]. NATURE, 2001, 410 (6824) : 50 - 56
  • [33] A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice
    Nakashima, E
    Oya, A
    Kubota, Y
    Kanada, N
    Matsushita, R
    Takeda, K
    Ichimura, F
    Kuno, K
    Mukaida, N
    Hirose, K
    Nakanishi, I
    Ujiie, T
    Matsushima, K
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (12) : 1896 - 1901
  • [34] Papadopoulos EJ, 1999, EUR J IMMUNOL, V29, P2551, DOI 10.1002/(SICI)1521-4141(199908)29:08<2551::AID-IMMU2551>3.0.CO
  • [35] 2-T
  • [36] Papadopoulos EJ, 2000, EUR J IMMUNOL, V30, P2355, DOI 10.1002/1521-4141(2000)30:8<2355::AID-IMMU2355>3.0.CO
  • [37] 2-#
  • [38] Chemokines
    Rollins, BJ
    [J]. BLOOD, 1997, 90 (03) : 909 - 928
  • [39] Cloning and characterization of a new type of mouse chemokine
    Rossi, DL
    Hardiman, G
    Copeland, NG
    Gilbert, DJ
    Jenkins, N
    Zlotnik, A
    Bazan, JF
    [J]. GENOMICS, 1998, 47 (02) : 163 - 170
  • [40] Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo
    Sharma, S
    Stolina, M
    Luo, J
    Strieter, RM
    Burdick, M
    Zhu, LX
    Batra, RK
    Dubinett, SM
    [J]. JOURNAL OF IMMUNOLOGY, 2000, 164 (09) : 4558 - 4563